The quantitative or qualitative decline of high-density lipoprotein (HDL) is linked to the pathogenesis of atherosclerosis because of its antiatherogenic functions, including the mediation of reverse cholesterol transport from the peripheral cells to the liver. We have recently shown that group X secretory phospholipase A 2 (sPLA 2 -X) is involved in the pathogenesis of atherosclerosis via potent lipolysis of lowdensity lipoprotein (LDL) leading to macrophage foam cell formation. We demonstrate here that sPLA 2 -X as well as group V secretory PLA 2 (sPLA 2 -V), another group of sPLA 2 that can potently hydrolyze phosphatidylcholine (PC), also possess potent hydrolytic potency for PC in HDL linked to the production of a large amount of unsaturated fatty acids and lysophosphatidylcholine (lysoPC). In contrast, the classical types of group IB and IIA secretory PLA 2 s evoked little, if any, lypolytic modification of HDL. Treatment with sPLA 2 -X or -V also caused an increase in the negative charge of HDL with no oxidation and little modification of apolipoprotein AI (apoAI). Modification with sPLA 2 -X or -V resulted in significant decrease in the capacity of HDL to cause cellular cholesterol efflux from lipid-loaded macrophages. Immunohistochemical analysis revealed significant expression of sPLA 2 -X in foam cell lesions in the arterial intima of Watanabe heritable hyperlipidemic (WHHL) rabbit. These findings suggest that lipolytic modification of HDL by sPLA 2 -X or -V causes drastic change of HDL in terms of the production of a large amount of unsaturated fatty acids and lysoPC linked to the reduction of its antiatherogenic functions. These sPLA 2 -mediated modifications of plasma lipoproteins might be relevant to the pathogenesis of atherosclerosis. D
Introduction
The plasma levels of high-density lipoproteins (HDL) are inversely related to the incidence of atherosclerosis and coronary artery disease [1] . The protective effects of HDL from atherosclerosis are attributed, in part, to reverse cholesterol transport, a process by which HDL can remove and deliver excess cholesterol from the peripheral cells to the liver [2, 3] . The first and essential step in this transport is the cholesterol efflux from plasma membranes of peripheral cells to HDL, with the phospholipid content and composition in HDL being a major factor determining the capacity of cholesterol efflux [4] . By stimulation of the cellular cholesterol efflux from arterial macrophages, HDL can inhibit the formation of foam cells that play an important role in fatty streak formation as well as in the formation of the complex lesions of plaque rupture [5] . Therefore, the loss of antiatherogenic functions of HDL by either qualitative or quantitative reduction can cause the generation and progression of atherosclerosis. Phospholipase A 2 s (PLA 2 s) are a diverse family of lipolytic enzymes that hydrolyze the sn-2 fatty acid ester bond of glycerophospholipids to produce free fatty acids and lysophospholipids [6, 7] . Among them, secretory PLA 2 s (sPLA 2 s) have several characteristics including a low molecular mass (13) (14) (15) (16) (17) (18) and an absolute catalytic requirement for millimolar concentrations of Ca 2 + [8, 9] , and are now classified into nine different groups in humans (IB, IIA, IID, IIE, IIF, III, V, X and XII) [8,10 -12] . A variety of circumstantial evidence suggests that sPLA 2 -induced hydrolysis of phospholipids in HDL plays a role in modulating HDL metabolism and function. For example, snake venom sPLA 2 can hydrolyze HDL phospholipids and alter the size and density, as well as the capacity of cholesterol efflux of HDL [4] , resulting in increased uptake by rat hepatocytes [13] . Among the endogenous sPLA 2 s, marked expression of group IIA sPLA 2 (sPLA 2 -IIA) has been reported in atherosclerotic lesions in humans [14] . In addition, sPLA 2 -IIAtransgenic mice exhibit decreased levels of HDL concomitant with increased atherosclerotic lesions [15] . Gesquiere et al. [16] have recently reported that group V sPLA 2 (sPLA 2 -V) has a potent hydrolyzing activity toward phosphatidylcholine (PC) and can induce the release of fatty acids from HDL more potently than sPLA 2 -IIA. Although there are few reports on sPLA 2 -V expression in atheroscrelotic lesions, these observations strongly suggest that the sPLA 2 family of enzymes may be involved in the development of atherosclerosis via their lipolytic activity on HDL.
Recently, we and other groups have shown that group X sPLA 2 (sPLA 2 -X) is one of the enzymes that possesses potent hydrolyzing activity toward PC [17] . In fact, sPLA 2 -X can induce potent release of arachidonic acid leading to cyclooxygenase-dependent prostaglandin formation, as well as marked production of lysophosphatidylcholine (lysoPC) in various cell types, including macrophages, spleen cells and colon cancer cells [18 -20] . More recently, we have shown that sPLA 2 -X can induce potent lipolysis of lowdensity lipoprotein (LDL) leading to the production of large amounts of unsaturated fatty acids and lysoPC [21] . The sPLA 2 -X-modified LDL was efficiently incorporated into macrophages to induce the accumulation of cellular cholesterol ester and the formation of non-membrane-bound lipid droplets in the cytoplasm [21] . These findings prompted us to examine the lipolytic effects of sPLA 2 -X on HDL functions.
In the present study, we first evaluated the potencies of sPLA 2 s with respect to the release of fatty acids and the contents of PC and lysoPC in HDL. We then compared the characteristics of sPLA 2 -modified HDL with oxidized HDL in terms of phospholipid composition, negative charge and apolipoprotein AI (apoAI) modification. We found that sPLA 2 -X as well as sPLA 2 -V can induce potent lipolysis of HDL leading to the reduction of its capacity for cholesterol efflux from lipid-loaded macrophages. We also report on the elevated expression of sPLA 2 -X in the foam cells in the atherosclerotic arterial wall of Watanabe heritable hyperlipidemic (WHHL) rabbit that is commonly used as the animal model of atherogenesis [22] .
Materials and methods
Purified recombinant proteins of human sPLA 2 -IB, sPLA 2 -V and sPLA 2 -X were prepared as described previously [17, 19] . Recombinant human sPLA 2 -IIA was a generous gift from Dr. Ruth Kramer (Eli Lilly, Indianapolis, USA). Rabbit anti-human sPLA 2 -X antibody (Ab) was prepared as described previously [19] , and anti-sPLA 2 -IB and anti-sPLA 2 -IIA Abs were purchased from Cayman Chemicals. Bovine serum albumin (BSA) was obtained from Sigma. Indoxam was synthesized at Shionogi Research Laboratories [23] .
Preparation of human HDL and modification with sPLA 2 s and CuSO 4 oxidation
Human HDL (d = 1.085 -1.21 g/ml) was isolated from the plasma of healthy and fasting donors by sequential ultracentrifugation, as described previously [24] . For modification of HDL with sPLA 2 s, 1 mg/ml HDL was incubated with various concentrations of sPLA 2 -IB, -IIA or -X at 37 jC in buffer composed of 1 mM CaCl 2 , 12.5 mM Tris -HCl (pH 8.0), 0.25 M NaCl and 0.0125% BSA. The reaction was stopped by addition of EDTA at the final concentration of 5 mM. For oxidative modification, 1 mg/ml HDL was incubated with 20 AM CuSO 4 at 37 jC, and then dialyzed against 150 mM NaCl containing 0.24 mM EDTA (pH 7.4). HDL prepared by incubation without any modification was used as native HDL.
2.2. Measurement of released fatty acids, PC and lysoPC in sPLA 2 -treated HDL Human HDL (1 mg/ml) was preincubated for 10 min at 37 jC and incubated with various concentrations of sPLA 2 enzymes in a final volume of 40 Al. The reaction was stopped by the addition of 160 Al of Dole's reagent, and the released fatty acids were extracted, labeled with 9-anthryldiazomethane (Funakoshi Co.), and then analyzed by reverse-phase HPLC on a LiChroCART 125-4 Supersphere 100 RP-18 column (Merck), as described previously [17, 25] .
For measurement of the amounts of PC and lysoPC in HDL, lipids were extracted with organic solvent, as described previously [18] . The extracted phospholipids were then separated by normal-phase HPLC on Ultrasphere silica 4.6 Â 250 mm (Beckman) connected with a guard column of 4.6 Â 45 mm using a solvent of acetonitrile/methanol/sulfuric acid (100:7:0.05, v/v/v) with a flow rate of 1 ml/min at room temperature. Fractions corresponding to authentic PC or L-a-lysoPC (Sigma), detected at the wavelength of 202 nm, were pooled and subjected to quantitative phosphorus analysis [26] . Following the modification with sPLA 2 s and CuSO 4 oxidation, lipid peroxidation was assessed by the following procedures. The peroxides were quantified in terms of thiobarbituric acid-reactive substances (TBARS) according to the methods of Nagano et al. [27] .
2.4. Analysis of electronic charge and apoAI in HDL modified with sPLA 2 s and oxidation
The electrophoretic mobility of HDL was analyzed with agarose gel electrophoresis (TITAN GEL Lipoproteins; Helena Laboratories, Japan), as described previously [28] . For analysis of apoAI modification, HDL was delipidated and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 4% acrylamide, as described previously [29] .
Measurement of cholesterol efflux by HDL from macrophage foam cells
Mouse resident peritoneal macrophages were obtained from the peritoneal cavity of female ICR mice (8 weeks). The cells were washed, resuspended in DMEM (Sigma) containing 10% FCS, and plated in 24-well plate (Costar) (5 Â 10 5 cells/well). Non-adherent cells were removed by washing, and adherent cells were incubated with acetyl LDL at 50 Ag/ml for 24 h. After incubation, the foamy macrophages were rinsed and incubated with DMEM containing 0.1% BSA for 24 h. Next, the macrophages were rinsed and incubated with either native or modified HDL at 100 Ag/ml for 24 h. The lipid extracts of the macrophages were prepared, evaporated, dissolved with isopropanol and the cholesterol mass was quantified by enzyme fluorometry [30] . The amount of esterified cholesterol was calculated by subtracting the free cholesterol from total cholesterol. The amounts of cellular proteins were quantified with a BCA Protein Assay reagent (PIERCE) after dissolving the cells in 0.2 N NaOH.
Immunohistochemistry
WHHL rabbits and New Zealand White (NZW) rabbits (8 months old) were sacrificed under pentobarbital anesthesia. Tissue samples were dissected from the aortic arch, thoracic, and abdominal aorta. They were immersion-fixed for 4 h in 4% paraformaldehyde, 0.1 M phosphate buffer, pH 7.2, and embedded in paraffin. Sections of paraffinembedded tissues were mounted onto polylysine-coated slides, dewaxed in xylene, rehydrated in alcohol, and blocked for endogenous peroxidase (0.3% H 2 O 2 in methanol). For sPLA 2 -IIA and macrophage immunohistochemistry, sections were reacted with monoclonal mouse antisPLA 2 -IIA Ab (5 Ag/ml) (Cayman; Ann Arbor MI) or monoclonal anti-rabbit macrophage Ab (1:200 dilution) (RAM-11, Dako, Carpinteria, CA), and immunoreaction was localized by using a Vectastain ABC kit (Vector Laboratories; Burlingame, CA). For sPLA 2 -X immunohistochemistry, the sections were subjected to reaction with biotin-conjugated rabbit anti-sPLA 2 -X Ab (17 Ag/ml), and immunoreaction was detected using tyramide signal amplification (TSA Biotin System; NEN Life Science Products, Boston, MA) and visualized with the peroxidase substrate, 3,3V-diaminobenzidine. The sections were counterstained with hematoxylin.
Results

Potent release of unsaturated fatty acids from HDL by sPLA 2 -X or -V
We first examined the potency of four types of human sPLA 2 (sPLA 2 -IB, -IIA, -V and -X at a concentration of 50 nM) for the release of fatty acids from human plasma HDL within 3 h. As shown in Fig. 1 , sPLA 2 -X induced a marked release of various types of unsaturated fatty acids in human HDL in the following order: linoleic acid (C18:2)>arach-idonic acid (C20:4)>oleic acid (C18:1)>docosahexaenoic acid (C22:6). sPLA 2 -V also released various types of unsaturated fatty acids from HDL, especially linoleic acid and oleic acid. sPLA 2 -X and -V elicited the release of these unsaturated fatty acids in a dose-dependent manner, and significant release could be detected at values as low as 5 nM (data not shown). Almost all of the released fatty acids are composed of these four types of fatty acids with little production of other types of unsaturated and saturated fatty acids (myristic acid, palmitic acid and stearic acid) during the treatments with sPLA 2 -V and -X (data not shown).
As shown in Fig. 2A , sPLA 2 -X induced a time-dependent release of unsaturated fatty acids from HDL, and the release response was almost saturated within 3 h. sPLA 2 -V also induced the release of unsaturated fatty acids with a similar time-dependency, but the total amount was slightly smaller than that of sPLA 2 -X especially within 6 h. sPLA 2 -IB was found to evoke a small but significant release of fatty acid only at 24 h. In contrast, there was little, if any, release with sPLA 2 -IIA and CuSO 4 treatment for 24 h. When focused on the arachidonic acid release (Fig. 2B) , sPLA 2 -X induced the most potent release among the sPLA 2 s examined. Although sPLA 2 -V released almost the same level of total fatty acids from HDL, its potency for the release of arachidonic acid was much lower compared to sPLA 2 -X. These results demonstrate that sPLA 2 -X and sPLA 2 -V could elicit potent release of unsaturated fatty acids from human HDL with different substrate specificities.
Effects of sPLA2-X and -V on the PC and lysoPC contents in HDL
Since PC is a major component of phospholipids in HDL, we next examined the PC content in HDL after treatment with sPLA 2 s and CuSO 4 . As shown in Fig. 3A , the amount of PC in HDL time-dependently decreased after treatment with sPLA 2 -X, -V and oxidation. Most of the PC was diminished in HDL by these treatments within 3 -6 h, and PC was completely degraded after 24 h treatment. Corresponding to the marked reduction of PC contents, a large amount of lysoPC was produced in HDL by treatment with sPLA 2 -X or -V within 3 h (Fig. 3B) . Incubation with sPLA 2 -specific inhibitor Indoxam (10 AM), which can block the enzymatic activities of both sPLA 2 s [17] , resulted in significant suppression of their lipolytic effects on HDL (data not shown). The time-dependency of PC degradation and lysoPC production by sPLA 2 -X and -V were correlated well with that of fatty acid releases (Fig. 2A) . Despite the similar PC degradation, the amount of lysoPC produced during oxidation by CuSO 4 was only about 15% of that induced by sPLA 2 -X or -V. In contrast, treatment with sPLA 2 -IB or -IIA caused little change in both PC and lysoPC contents in HDL.
Treatment of HDL with CuSO 4 caused a dramatic increase in TBARS (Table 1) as well as significant production of conjugated dienes (data not shown), whereas treatment with four types of sPLA 2 s did not alter these oxidative parameters. These findings demonstrate that sPLA 2 -X and -V induce PC hydrolysis in HDL leading to the production of a large amount of lysoPC and unsaturated fatty acids without any oxidative modification.
Effect of sPLA 2 -X and -V on electronic mobility and apoAI in HDL
We next examined the effects of sPLA 2 treatment on the electronic charge of HDL with agarose gel electrophoresis. As shown in Fig. 4 , increased anodic migration was observed in HDL after 24 h oxidation with CuSO 4 . Treatment with sPLA 2 -X or -V also caused enhanced mobility of HDL and marked migration was detected even after 3 h of incubation. In contrast, the mobility of HDL after treatment with sPLA 2 -IB or -IIA was not changed during 24 h of incubation. Addition of anti-sPLA 2 -X Ab (100 Ag/ml), which was proven to inhibit the enzymatic activity of sPLA 2 -X [17] , resulted in complete blockade of sPLA 2 -Xinduced mobilization (data not shown). SDS-PAGE analysis has also revealed little, if any, denaturation of apoAI after sPLA 2 -X or -V treatments for 24 h, which contrasted with an exaggerated aggregation of apoAI in CuSO 4 -treated HDL (data not shown). These results demonstrate that sPLA 2 -X and -V can induce an increase of the negative charge of HDL without any modification of apoAI.
Effect of sPLA 2 -X and -V on cellular cholesterol efflux by HDL
One of the most important functions for antiatherogenic property of HDL is the mediation of cellular cholesterol efflux, and the characteristics of phospholipids in HDL in terms of contents and composition is a major factor determining the cholesterol efflux capacity from the cells to HDL [4] . Since sPLA 2 -X or -V treatment cause a dramatic decrease in PC along with the increase in lysoPC, we compared the cholesterol efflux capacity between native and modified HDL from acetyl LDL-pretreated macrophages that accumulated cholesterol ester in the cytoplasm. As shown in Fig. 5 , incubation with native HDL (100 Ag/ ml) resulted in ca. 83% decrease in the mass of cholesteryl ester accumulated in the lipid-loaded macrophages, and sPLA 2 -IB or -IIA-treated HDL possessed a similar efficacy. In contrast, sPLA 2 -X or -V-modified HDL caused only about 60% reduction, indicating a significant decrease in the capacity to mediate cholesterol efflux. At 50 Ag/ml of HDL, similar decrease in cellular cholesterol efflux could be detected in sPLA 2 -X or -V-modified HDL (data not shown). These results suggest that sPLA 2 -X and -V can deprive HDL of the capacity to induce cholesterol efflux by causing the alteration of the phospholipid content and composition in HDL.
Expression of sPLA 2 -X in atherosclerotic lesions of WHHL rabbits
In order to examine the localization of sPLA 2 -X in the atherosclerotic lesions, we used WHHL rabbits, a familiar model of atherogenesis [22] . Fig. 6A shows atherosclerotic lesions in the aorta of WHHL rabbits. Large foam cells filled with numerous lipid droplets and cholesterol crystals were observed between the middle and deep parts of the intimal ) for the indicated times, and the electrophoretic mobility was analyzed by agarose gel electrophoresis (25 min at 90 V) followed by staining with fat red 7B.
lesion. In the aorta of age-and sex-matched NZW rabbits, no intimal thickening was found (data not shown). Fig. 6B shows the result of immunostaining of WHHL aorta with a monoclonal Ab against rabbit macrophage, RAM-11. Cells with foam cell morphology were intensely stained with To analyze the expression of sPLA 2 -X in atherosclerotic lesion by immunohistochemistry, we used biotinylated rabbit anti-human sPLA 2 -X polyclonal Ab. By ELISA and immunoblotting analysis, we confirmed that this Ab specifically binds to human sPLA 2 -X with no cross-reactivity for other human sPLA 2 s (-IB, -IIA, and -V) and also recognizes rabbit sPLA 2 -X (data not shown). Polyclonal anti-sPLA 2 -X Ab stained the foam cells in the intima (Fig. 6C) , and immunoreaction was diffuse through the middle to deep region of the intima, with most of the foam cells being positive. Moderate staining was also found in the endothelium, but it was non-specific because preincubation of the Ab with 50-fold (in the molar ratio) excess amount of recombinant rabbit sPLA 2 -X completely abolished the staining of foam cells, but not that of the endothelium (data not shown). No immunoreaction of sPLA 2 -X was found in atherosclerosis-free aorta from NZW rabbits. To examine the localization of sPLA 2 -IIA, we used mouse anti-human sPLA 2 -IIA monoclonal Ab. By immunoblotting analysis, we confirmed that this Ab specifically binds to sPLA 2 -IIA with no cross-reactivity for other human sPLA 2 s (-IB, -V and -X), as well as rabbit sPLA 2 -X (data not shown). Prior to immunostaining of aorta, we tested the availability of the Ab using rabbit jejunum sections as a positive control. We detected positive signals in Paneth cells that have been reported to extensively express sPLA 2 -IIA in rats and humans [31, 32] , demonstrating that the anti-human sPLA 2 -IIA Ab we used could cross-react with the counterpart of rabbit origin. As shown in Fig. 6D , positive cells were detected in the middle to deep region of the intima and had the morphology of foam cells. There was great variation in the degree of immunoreactivity among the foam cells in the lesion from intense staining to total absence of staining. These staining patterns of sPLA 2 -X and -IIA were similar among the aortic arch, thoracic, and abdominal aorta (data not shown), indicating that both sPLA 2 -X and -IIA are expressed in foamy macrophages in the atherosclerotic lesions of WHHL rabbits.
Discussion
Epidemiological studies have established that plasma HDL concentrations are inversely related to the development of coronary heart disease [33] . The formation of atherosclerotic lesions regressed by infusion of HDL to cholesterol-fed rabbits [34] and transgenic mice overexpressing human apoAI showed an increased plasma level of HDL and resisted atherosclerosis induced by high-fat diet [35] or apolipoprotein E (apoE) deficiency [36] . Thus, the loss of antiatherogenic functions of HDL as well as the decline of plasma HDL concentration is linked to the increase in the risk of developing atherosclerosis. In the present study, we have shown that sPLA 2 -X and -V induced a potent lipolytic modification of HDL including complete hydrolysis of PC linked to the production of large amounts of unsaturated fatty acids and lysoPC. sPLA 2 -X or -Vmodified HDL shows features in common with oxidized HDL in terms of the reduction of PC as well as an increase in the negative charge. However, marked differences were observed in several aspects between these modifications. The increase in lysoPC production during sPLA 2 -X or -V treatment was accompanied by the release of large amounts of unsaturated fatty acids, whereas there was no release response during HDL oxidation. Higher levels of lysoPC production were detected in sPLA 2 -X or -V-treated HDL compared to oxidized HDL despite a similar PC degradation (Fig. 3) . As lysoPC is believed to play an important role in atherosclerosis and inflammatory diseases by altering various cellular functions, such as the induction of various chemokines and cell adhesion molecules [37, 38] , sPLA 2 -X or -V-modified HDL might evoke more proatherogenic cellular events compared to oxidized HDL.
It has been known that scavenger receptor B type I (SR-BI) can act as the HDL receptor to stimulate cholesterol efflux from foamy macrophages, and the efflux rate is correlated with SR-BI expression levels in various cell lines [39] . In the SR-BI-mediated cholesterol efflux, phospholipids present in the acceptor HDL are essential factors, because the cholesterol efflux is highly correlated with the concentration of HDL phospholipids in serum and stimulated by phospholipid supplementation of serum [40] . Since sPLA 2 -X and -V induced strong degradation of PC, a major component of phospholipids in HDL, the reduction of the capacity to induce cellular cholesterol efflux in sPLA 2 -X or -V-modified HDL (Fig. 6 ) might be due to a decrease in the SR-BI-mediated responses. Alternatively, the ATP-binding cassette transporter ABCA1 might be involved in this process, as it has been known to mediate the transport of cellular cholesterol to lipid-poor HDL apolipoproteins [41, 42] . In fact, mutations in ABCA1 cause Tangier disease [41,43 -45] , a severe HDL deficiency syndrome characterized by deposition of cholesterol in tissue macrophages and prevalent atherosclerosis [46] . Recent studies have shown that unsaturated fatty acids reduce the macrophage ABCA1 content by enhancing its degradation rate [47] . As sPLA 2 -X and -V can release a large amount of unsaturated fatty acids from HDL (Fig. 1) , these fatty acids might reduce the ABCA1 content in macrophages leading to decline of the cellular cholesterol efflux. Since HDL possesses various antiatherogenic functions, including the protection of LDL from oxidation [48 -50] , the inhibition of platelet aggregation [51, 52] and the protection of endothelial cells from oxidative stress and apoptosis [53] , the effects of sPLA 2 -X or -V modification on these biological events should also be examined in future studies.
Among the human sPLA 2 s examined, potent lipolysis of HDL was observed only on treatment with sPLA 2 -X and -V, which may have been due to higher hydrolyzing activity toward PC, the major phospholipid species in HDL [17, 54] . Weak fatty acid release was detected during treatment of HDL with higher concentrations of sPLA 2 -IB (Fig. 2) . However, sPLA 2 -IB is mainly expressed in the pancreas and its expression was not detected in the atherosclerotic lesions of humans [55] and apoE-deficient mice [21] , indicating that its role in atherogenesis is quite minor. With regard to sPLA 2 -IIA, its expression was markedly elevated in human atherosclerotic arterial intima, where most of the sPLA 2 -IIA is localized along the extracellular matrix, associated with collagen fibers and other structures [56, 57] . In the present study, we found that sPLA 2 -IIA is expressed in a small population of foam cells in the intimal lesion of WHHL rabbits (Fig. 6D ). This observation is consistent with the report by Menschikowski et al. [14] , in which the expression of sPLA 2 -IIA was detected in some, but not all, foam cells in human atherosclerotic plaques. In contrast, the expression of sPLA 2 -X was detected in the foam cells throughout the atherosclerotic intima in WHHL rabbits (Fig. 6C) , similar to its distribution in high-fat fed apoE-deficient mice [21] . The different localizations between sPLA 2 -IIA and -X suggests their distinct pathophysiological roles in the initiation and progression of atherosclerotic plaques. We found that the potency of sPLA 2 -IIA in HDL modification in terms of PC degradation and cellular functions is much lower than sPLA 2 -X, and this type of sPLA 2 has been shown to induce the enhanced retention of lipoproteins to human aortic proteoglycans [58, 59] . These findings suggest that sPLA 2 -IIA is involved in the accumulation of extracellular lipoproteins in the proteoglycan-rich subendothelial layer of the arterial intima, whereas sPLA 2 -V and -X induce more powerful lipolysis of HDL linked to the reduction of its antiatherogenic effect within the arterial intima. Recent studies have shown that overexpression of sPLA 2 -IIA resulted in increased rate of catabolism and altered sites of tissue uptake of HDL in mice [60] . The contribution of sPLA 2 -X to HDL modifications in pathological states should also be clarified in future genetic studies including the generation of mice deficient in sPLA 2 -X.
In the present study, sPLA 2 -V was also found to hydrolyze PC in HDL and release a large amount of unsaturated fatty acids. However, as reported by Gesquiere et al. [16] , sPLA 2 -V released more linoleic acid (over 10-fold) than arachidonic acid from HDL ( Fig. 1) , which corresponded well with its fatty acid specificity using synthetic substrate [61] . In contrast, sPLA 2 -X can induce potent release of arachidonic acid from HDL with over half the levels of linoleic acid (Fig. 1) , and its potency for arachidonic acid release was much higher than sPLA 2 -V (Fig. 2B) , suggesting its greater relevance to the production of proatherogenic eicosanoids [62, 63] . Although sPLA 2 -V is secreted by macrophages and mast cells [64] , there have been few reports on its expression in pathological states including atheroscrelotic lesions. This may be due to the difficulty of generating sPLA 2 -V-specific Ab applicable for immunohistochemistry, as many Abs for sPLA 2 -IIA have been shown to cross-react with sPLA 2 -V because of their structural similarity [64] . In the present study, we confirmed no cross-reactivity of anti-sPLA 2 -IIA Ab for human sPLA 2 -IB, -V and -X, as well as rabbit sPLA 2 -X. However, there was no data showing the absence of its cross-reactivity with rabbit sPLA 2 -V, suggesting that positive signals detected in the atherosclerotic lesions in WHHL rabbits might also represent the expression of this enzyme. Nevertheless, these observations strongly suggest that sPLA 2 family enzymes may be involved in the development of atherosclerosis via modification of HDL.
In conclusion, we have demonstrated here that sPLA 2 -X or -V can induce lipolytic modification of HDL leading to a decrease in its ability to mediate the cellular cholesterol efflux. Since sPLA 2 -X and -V can also evoke potent modification of LDL [16, 21] , these sPLA 2 s may be responsible for the generation of atherogenic lipoprotein particles leading to the formation and progression of fatty streaks in atherosclerotic regions. In addition, a variety of lipid mediators including polyunsaturated fatty acids, eicosanoids and lysoPC can be generated during the lipolytic process of lipoproteins, which may also contribute to the progression of atherosclerosis. Further studies regarding the expression of sPLA 2 -X or -V in human atherosclerotic lesions as well as its circulating levels in patients with atherosclerosis are required for further understanding of its pathological roles in humans as well as the strategies of sPLA 2 inhibitors as antiatherogenic drugs.
